Trial Search Results

The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology

The goal of this study is to evaluate if vasopressin can elevate systemic arterial blood pressures without having a significant effect on pulmonary arterial pressures. Because patients who have undergone Fontan procedures rely on low pressures across the pulmonary vascular bed to maintain cardiac output, vasoactive agents that concomitantly increase systemic and pulmonary pressures may have a deleterious effect in this specific patient population.

Hypothesis: In patients with Fontan physiology, vasopressin will increase systemic BP by 20% above baseline, without increasing the transpulmonary gradient.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Vasopressin


Early Phase 1


Inclusion Criteria:

1. All patients scheduled for cardiac catheterization at Lucile Packard Children's Hospital
with Fontan circulation

Exclusion criteria:

   1. Critical illness severe enough to preclude extended cardiac catheterization time

   2. Patients already on vasopressin

   3. Patients with pulmonary hypertension.

   4. Patient not scheduled for cardiac catheterization at Lucile Packard Children's
   Hospital (LPCH).

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Manchula Navaratnam, MD